Table 13.
Various NLC formulations prepared by different methods and their intervention in the treatment or management of breast cancer.
| Nanocarrier | Method of preparation | Interventions | Reference |
|---|---|---|---|
| Cabazitaxel (CBZ-loaded NLCs) | Hot homogenization method | NLCs containing CBZ induced a 6- and 2.5-fold increase in cytotoxicity, as well as an increase in apoptosis. In vitro cell culture assays, MDA-MB-468 and MCF-7 cells had reduced motility. In cells, NLC absorption was 2.5 to 2.1 times that of CBZ alone. For tumors that are resistant to drugs. |
[151] |
| Luteolin (LTN)-encapsulated chitosan (CS) (LTN-CS-NLCs) |
Melt emulsification ultrasonication technique | Mucoadhesion, gastro-intestinal stability, and intestinal penetration were all significantly improved in LTN-CS-NLCs. MDA-MB-231 and MCF-7 cells showed improved antioxidant activity as well as dose and time-dependent cytotoxicity. LTN-NLCs coated with chitosan show a lot of potential in the treatment of Breast cancer. |
[152] |
| NLC loaded with Imatinib (NANIMA) | Hot homogenization method | The particle size of 104.63 ± 9.55 d.nm, PDI of 0.227 ± 0.06, and EE of 99.79 ± 0.03 and was sustained released. In cytotoxicity experiments on MCF-7 breast cancer cells, optimum NANIMA (IC50 = 6 M) was shown to be 8.75 times more effective than IMA alone (IC50 = 52.5 M). For the treatment of breast cancer, a lower dose of IMA-rich NLC will suffice rather than IMA alone. Furthermore, NANIMA has less adverse effects than IMA alone, leading in a satisfactory therapeutic outcome in the treatment of breast cancer. |
[153] |
| Raloxifene | Ultrasonication method |
In vitro, the RLN-NLCs were more cytotoxic to MCF-7 cells than the RLN solution. An ex vivo intestinal systemic absorption analysis revealed that the RLN-NLCs had better intestinal permeability. When RLN-NLCs were compared to RLN solution in an in vivo pharmacokinetic investigation in female Wistar rats, the oral bioavailability of RLN from RLN-NLCs increased 4.79-fold. One of the paths for a novel nanotherapeutic approach to the treatment of Breast cancer. |
[154] |
| Curcumin-Loaded Magnetic Lipid Nanoparticles (CUR-NLC-SPIONs) |
SPIONs by co-precipitation followed by CUR-NLC-SPIONs by homogenization technique | The average PS was 166.7 ± 14.20 nm, with a mean ZP- −27.6 ± 3.83 mv, PDI of 0.24 ± 0.14, EE was 99.95 ± 0.015%, and drug-loading capacity was 3.76 ± 0.005%. CUR-NLC-SPIONs had a more substantial cytotoxic effect against human breast cancer cells than free CUR. This new drug delivery technology, which uses superparamagnetic properties, might be utilized to create new biocompatible drug carriers and tailored cancer therapies. |
[155] |
| Curcumin | High shear hot homogenization method | The small mean PS, spherical shape and negative ZP of NLCs assisted their internalization into cells. By regulating and suppressing P-gp expression, glyceryl monooleate enhanced the cytotoxic effects of CUR. | [156] |
| Docetaxel-loaded NLCs functionalized with trastuzumab (Herceptin) | Solvent extraction technique followed by probe sonication. | DTX added in chemically connected NLCs to Herceptin had more cytotoxic effects than physically coated nanoparticles. The Herceptin conjugated NLCs seem to have the potential for delivering DTX to HER2-positive breast cancer cells in a targeted way. |
[157] |